April 4, 2016 – TARRYTOWN, N.Y., – PGI Drug Discovery LLC (PsychoGenics), today announced that a compound identified through its drug discovery collaboration with Sunovion Pharmaceuticals Inc. (Sunovion) has achieved a milestone. Read More.
January 27, 2016 – TARRYTOWN, N.Y., – PsychoGenics announced today that it has obtained a license from University of California, San Diego to its Line-41 mouse model of Alzheimer’s disease, expressing human APP with the Swedish (K670N/M671L) and London (V717I) mutations under the control of the murine-Thy-1 promoter. Read More.
January 19, 2016 – TARRYTOWN, N.Y., – PsychoGenics Inc. (PsychoGenics) announced today that it has acquired equipment and hired experienced scientists from Lundbeck Research USA and is now in a position to offer expanded services in the areas of bioanalysis, in vivo microdialysis, EEG and quantitative histology. In August 2015, Lundbeck announced that it will close its research operation in Paramus NJ. Following this announcement PsychoGenics and Lundbeck began discussions to preserve jobs, which has now been accomplished. Read More.
January 12, 2016 – NEW YORK, N.Y., – PsychoGenics Inc. and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a new partnership to bring PsychoGenics’ validated Alzheimer’s animal models and experimental services to ADDF grantees working on preclinical Alzheimer’s drug discovery programs. Through the partnership, PsychoGenics will establish risk-sharing agreements with ADDF-funded biotechnology companies to make its services available under extremely favorable financial terms, thus increasing the value of the ADDF’s grants. Read More.